MOG-antibody-associated disease is different from MS and NMO and should be considered as a distinct disease entity – No

Lucchinetti C Bruck W Parisi J , et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47(6): 707–717.

Lennon VA Wingerchuk DM Kryzer TJ , et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364(9451): 2106–2112.

Marignier R Bernard-Valnet R Giraudon P , et al. Aquaporin-4 antibody-negative neuromyelitis optica: Distinct assay sensitivity-dependent entity. Neurology 2013; 80(24): 2194–2200.

Sato DK Callegaro D Lana-Peixoto MA , et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82: 474–481.

Jurynczyk M Tackley G Kong Y , et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry 2017; 88(2): 132–136.

Mariotto S Ferrari S Gastaldi M , et al. Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. J Neurol Neurosurg Psychiatry. Epub ahead of print 5 April 2019. DOI: 10.1136/jnnp-2018-320287.

Cobo-Calvo A Ruiz A Maillart E , et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study. Neurology 2018; 90(21): e1858–e1869.

Lassmann H. The changing concepts in the neuropathology of acquired demyelinating central nervous system disorders. Curr Opin Neurol 2019; 32(3): 313–319.

Quintana FJ Farez MF Viglietta V , et al. Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci USA 2008; 105(48): 18889–18894.

Linington C Engelhardt B Kapocs G , et al. Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J Neuroimmunol 1992; 40(2–3): 219–224.